Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

Part of paid clinical trials in Winston-Salem, North Carolina.

Sponsor
Wake Forest University
Study ID
NCT00690911
Phase
PHASE2
Status
Withdrawn

Conditions

  • Sarcoidosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • adalimumab — DRUG
    40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.

Study Details

The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.

Key Dates

Status verified
Nov 2017

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    open label adalimumab 40mg

Primary Outcome Measure

Change in PGA score. [ Time Frame: 24 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Wake Forest University Health Sciences DermatologyWinston-SalemNorth Carolina27157-

Find similar trials in Winston-Salem, NC

By research site
Wake Forest University Health Sciences Dermatology· Winston-Salem, NC

Related Studies